%0 Journal Article
%T Optimal duration of adjuvant endocrine therapy: how to apply the newest data
%A Belgin Korkmaz
%A Florian Fitzal
%A Kerstin Wimmer
%A Michael Bolliger
%A Michael Gnant
%A Ruth Exner
%A Stephanie Strobl
%A Yelena Devyatko
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2017
%R 10.1177/1758834017732966
%X The benefit of 5 years of adjuvant endocrine therapy for women with hormone receptor-positive (HR+) breast cancer (BC) is beyond discussion. Nevertheless, the risk of recurrence of luminal BC persists for 15 years or more after diagnosis. Consequently, approaches of extended adjuvant therapy have been investigated in large clinical trials, with the ultimate aim of further reducing the risk of recurrence in patients with HR+ BC
%K adjuvant therapy
%K early breast cancer
%K extended adjuvant therapy
%K hormone receptor-positive breast cancer
%K postmenopausal
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764154/